US accuses Regeneron of fraudulent price reporting for eye drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
RBC on Regeneron Pharma (REGN):'The Buying Opportunity Many Have Been Looking For, With Overdone DOJ Downside On Top Of Recent Weakness'
April 11, 2024 11:40 AM EDTRBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $1,189.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "We note that DOJ has filed a complaint against REGN, accusing the company of fraudulently inflating Medicare reimbursement rates for Eylea. To our read, this is in regard to REGN's practice in reimbursing credit card transaction fees to distributors that occurred when physicians purchased the product using credit cards. While we do not know what the exact damages would be in case of potential settlement, given the complaint highlighting $250M in... More
